Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
Head & Neck|August 25, 2016
Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapyAron Popovtzer, Hanna Burnstein, Salomon Stemmer, et al.International Journal of Radiation Oncology, Biology, Physics|July 13, 2024
Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing-Initial Report of the SABR-Dual TrialElisha Fredman, Assaf Moore, Oded Icht, et al.Journal of Neuro-Oncology|July 6, 2016
Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumorsDeborah T Blumenthal, Michal Yalon, Gilad W Vainer, et al.Magma (New York, N.Y.)|October 26, 2022
Model-free dynamic contrast-enhanced MRI analysis: differentiation between active tumor and necrotic tissue in patients with glioblastomaIdan Bressler, Dafna Ben Bashat, Yuval Buchsweiler, et al.Journal of Neurosurgery|July 4, 2025
Let the light in: influence of fluorescence-guided resection with 5-aminolevulinic acid on surgical outcomes, extent of resection, and survival in subventricular zone glioblastomaYosef Laviv, Paz Lev, Sapir Lev, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|December 19, 2015
Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapyElizabeth Dudnik, Tali Siegal, Leor Zach, et al.Advances in Radiation Oncology|December 6, 2017
Single fraction stereotactic radiosurgery for multiple brain metastasesDror Limon, Frances McSherry, James Herndon, et al.Journal of Neuro-Oncology|March 12, 2025
Long-term impact of bevacizumab for the treatment of brain radiation necrosisHila Nobel, Jonathan Ofer, Sara Faye Borenstein, et al.Neuro-Oncology Advances|October 21, 2024
A phase II, open-label, single-arm trial of pembrolizumab for recurrent meningioma and solitary fibrous tumorDror Limon, Alexandra Amiel, Shaked Even Haim, et al.Neuro-Oncology Advances|October 30, 2024
Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteriaSara Faye Borenstein, Ruth Eliahou, Alexandra Amiel, et al.Pageof 5